Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
15 June 2021 - 6:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2021
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
This Report on Form 6-K is hereby incorporated
by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-227753) and Form F-3 (File Nos. 333-195124,
333-236064, and 333-249063), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents
or reports subsequently filed or furnished.
On June 11, 2021, Israel Shamay, an external director
of Can-Fite BioPharma Ltd. (the “Company”), passed away. Mr. Shamay had served as an external director of the Company since
December 2014, and as a member on both the Company’s Audit Committee and Compensation Committee.
Mr. Shamay served as Executive Director, Strategic
Initiatives and Head of the Americas Operations of MATIMOP (Israeli Industry Center for R&D), the International Operations agency
of the Israeli Office of the Israel Innovation Authority (formerly the Office of Chief Scientist) since 2012. He will be missed by the
Company.
The Company sends its wishes of condolences to Mr. Shamay’s wife
and children.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: June 14, 2021
|
By:
|
/s/ Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2024 to May 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From May 2023 to May 2024